Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawFetal Tissue, Stem Cells & Bioethics

CLI Vice Pres. Dr. Prentice on Human Embryo Genetic Manipulation: “Modest but Meaningful Protection”

 

On December 17, 2015, Townhall published an op-ed by CLI Vice President Dr. David Prentice on the only new pro-life item in the federal Omnibus funding bill. Rep. Robert Aderholt (R-Ala.) proposed language to the bill to prevent the approval of the creation or use of genetically-manipulated human embryos in a clinical setting.

 

Though the Dickey-Wicker Amendment, first enacted in 1996, already prohibits federal funding of research that creates or destroys a human embryo, says Dr. Prentice, this new language fills a gap in the process so that the Food and Drug Administration (FDA) is precluded from even entertaining approval of any research submissions “in which a human embryo is intentionally created or modified to include a heritable genetic modification.”

 

While the new language puts a pause on genetic experiments on human embryos, Dr. Prentice stresses that it “does not in any way hinder genetic therapies or trials for born individuals” and that it still allows “necessary research for authentic treatments to continue unabated.”

 

To read the full op-ed in Townhall, please see: https://townhall.com/columnists/davidaprentice/2015/12/17/modest-but-meaningful-protection-from-human-embryo-genetic-manipulation-n2094746

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

A person in a white shirt dropping an abortion ballot into a white box against a yellow background.

Abortion on the Ballot in November

October 2, 2026

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image